Pluri Inc.
PLUR
Price:
$5.3105
Market Cap:
$28.62M
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantat...[Read more]
Industry
Biotechnology
IPO Date
2003-06-30
Stock Exchange
NASDAQ
Ticker
PLUR
The ROE as of September 2024 (TTM) for Pluri Inc. (PLUR) is -250.46%
According to Pluri Inc.’s latest financial reports and current stock price. The company's current ROE is -250.46%. This represents a change of -175.44% compared to the average of 332.01% of the last 4 quarters.
Pluri Inc. (PLUR) Historical ROE (quarterly & annually)
How has PLUR ROE performed in the past?
The mean historical ROE of Pluri Inc. over the last ten years is -98.00%. The current -250.46% ROE has changed 155.57% with respect to the historical average. Over the past ten years (40 quarters), PLUR's ROE was at its highest in in the March 2024 quarter at 1.49%. The ROE was at its lowest in in the March 2019 quarter at -116.82%.
Average
-98.00%
Median
-89.52%
Minimum
-212.06%
Maximum
-42.44%
Pluri Inc. (PLUR) ROE by Quarter and Year
Discovering the peaks and valleys of Pluri Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 76.08%
Maximum Annual ROE = -42.44%
Minimum Annual Increase = -67.58%
Minimum Annual ROE = -212.06%
| Year | ROE | Change |
|---|---|---|
| 2023 | -212.06% | 55.28% |
| 2022 | -136.57% | 56.28% |
| 2021 | -87.39% | 67.05% |
| 2020 | -52.31% | -67.58% |
| 2019 | -161.37% | 76.08% |
| 2018 | -91.65% | -0.32% |
| 2017 | -91.94% | 50.92% |
| 2016 | -60.92% | 43.55% |
| 2015 | -42.44% | -2.10% |
| 2014 | -43.35% | 17.76% |
Pluri Inc. (PLUR) Average ROE
How has PLUR ROE performed in the past?
The current ROE of Pluri Inc. (PLUR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-145.34%
5-year avg
-129.94%
10-year avg
-98.00%
Pluri Inc. (PLUR) ROE vs. Peers
How is PLUR’s ROE compared to its peers?
Pluri Inc.’s ROE is greater than BioLineRx Ltd. (-225.62%), greater than Purple Biotech Ltd. (-48.16%), greater than Aridis Pharmaceuticals, Inc. (-21.32%), greater than Enlivex Therapeutics Ltd. (-71.76%), greater than Transgene SA (-178.29%), greater than Eupraxia Pharmaceuticals Inc. (-198.59%), less than Champions Oncology, Inc. (323.52%), greater than MAIA Biotechnology, Inc. (-18051.81%), greater than Lumos Pharma, Inc. (-157.99%), greater than Evogene Ltd. (-189.58%), greater than Arcus Biosciences, Inc. (-42.86%), greater than Fate Therapeutics, Inc. (-44.09%), greater than Surface Oncology, Inc. (-113.52%), greater than Compugen Ltd. (-16.10%), greater than BiomX Inc. (-121.74%), greater than MediWound Ltd. (-75.57%), less than Foghorn Therapeutics Inc. (140.34%), greater than Eliem Therapeutics, Inc. (-47.03%), greater than Sutro Biopharma, Inc. (-97.19%), greater than Dyadic International, Inc. (-145.95%),
| Company | ROE | Market cap |
|---|---|---|
| -225.62% | $55.73M | |
| -48.16% | $12.30M | |
| -21.32% | $44.57K | |
| -71.76% | $32.54M | |
| -178.29% | $209.81M | |
| -198.59% | $108.29M | |
| 323.52% | $69.76M | |
| -18051.81% | $71.72M | |
| -157.99% | $31.52M | |
| -189.58% | $14.85M | |
| -42.86% | $1.55B | |
| -44.09% | $451.53M | |
| -113.52% | $65.08M | |
| -16.10% | $174.15M | |
| -121.74% | $17.63M | |
| -75.57% | $195.88M | |
| 140.34% | $511.24M | |
| -47.03% | $550.56M | |
| -97.19% | $320.07M | |
| -145.95% | $37.14M |
Build a custom stock screener for Pluri Inc. (PLUR) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Pluri Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Pluri Inc. (PLUR) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Pluri Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Pluri Inc.'s ROE?
How is the ROE calculated for Pluri Inc. (PLUR)?
What is the highest ROE for Pluri Inc. (PLUR)?
What is the 3-year average ROE for Pluri Inc. (PLUR)?
What is the 5-year average ROE for Pluri Inc. (PLUR)?
How does the current ROE for Pluri Inc. (PLUR) compare to its historical average?